Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.

导出 OA

翻译打印收藏纠错

第一作者： Rebekka,Duhen

第一单位： Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. rebekka.duhen@providence.org.

作者： Rebekka,Duhen ^[1] ; Carmen,Ballesteros-Merino ^[2] ; Alexandra K,Frye ^[2] ; Eric,Tran ^[2] ; Venkatesh,Rajamanickam ^[2] ; Shu-Ching,Chang ^[3] ; Yoshinobu,Koguchi ^[2] ; Carlo B,Bifulco ^[2] ; Brady,Bernard ^[4] ; Rom S,Leidner ^[2] ; Brendan D,Curti ^[2] ; Bernard A,Fox ^[2] ; Walter J,Urba ^[2] ; R Bryan,Bell ^[2] ; Andrew D,Weinberg ^[2]

作者单位： Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. rebekka.duhen@providence.org. ^[1] Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. ^[2] Medical Data Research Center, Providence Saint Joseph's Health, Portland, OR, USA. ^[3] Molecular Genomics Laboratory, Providence St. Joseph Health, Portland, OR, USA. ^[4] Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. andrew.weinberg@providence.org. ^[5] AgonOx, Inc., Portland, OR, USA. andrew.weinberg@providence.org. ^[6]